News & Alerts

Call to Action Online – April 30, 2022

April 30, 2022

Are you joining us at the in-person Advocate Leadership Summit in Washington DC today? 

We’re excited to be bold this weekend at the Summit! The Summit provides unparalleled training and education for advocates who want to gain the knowledge necessary to challenge breast cancer science and research. NBCC trained advocates help support our mission to end breast cancer.

  • WHEN: April 30 – May 2, 2022, followed by NBCC’s Annual Lobby Day on May 3
  • WHERE: Park Hyatt Hotel, Washington, DC
  • WHO: Passionate advocates who want to end breast cancer.

Make sure you follow us on Twitter, Instagram, and Facebook and share your photos and posts with us!


NBCC’s Work on Breast Cancer Vaccine Recognized Nationally  

In 2010, frustrated by the lack of innovation in breast cancer, NBCC launched the Artemis Project and began work on a preventive vaccine. When NBCC started that work more than ten years ago, most in the world of breast cancer were skeptical at the very least. And, more often, dismissive. “…a Nature editorial dismissed… [NBCC’s] goal of developing a preventive vaccine by 2020 as “misguided,”…” But we persevered and now others have caught up. NBCC’s work on the Artemis preventive breast cancer vaccine was recently covered in a Science Magazine article that addresses the progress and benefits of this work.

Read more about the breakthrough in vaccine development to prevent cancer here.


Donate Today

The National Breast Cancer Coalition’s mission is to end breast cancer. Every dollar raised is immediately put to work funding scientific research, collaborative workshops and symposia, advocacy training, and public policy work in Washington, DC, and in state capitals across the country in support of our mission.

Every minute counts in our efforts to achieve the goal of ending breast cancer. Every dollar equates to more lives saved.

Your gift is more than a contribution. It is an investment that will enable us to end breast cancer, once and for all.